Business Context and Reporting Period
Company: Curis, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Curis is a therapeutic drug development company focused on modulating regulatory signaling pathways (Hedgehog, BMP, Wnt) to repair and regenerate human tissues. The company operates in a single segment: developmental biology products. It has no manufacturing or sales infrastructure and relies on strategic collaborations for development and commercialization.
Key Financial Metrics
| Metric | 2004 | 2003 |
|---|---|---|
| Total Revenues | $4.95 million | $11.05 million |
| Net Loss | $(13.90) million | $(11.62) million |
| Net Loss Per Share (Basic/Diluted) | $(0.33) | $(0.33) |
| Cash, Cash Equivalents, and Marketable Securities | $49.51 million | $35.15 million |
| Working Capital | $45.78 million | $34.09 million |
| Accumulated Deficit | $(662.97) million | $(649.07) million |
| Long-Term Debt (Convertible Notes) | $5.71 million | $5.33 million |
Note: The company has never been profitable and expects to incur significant operating losses for the foreseeable future.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 55% to $4.95 million from $11.05 million in 2003. This was primarily driven by a drop in license fee revenue ($1.50 million vs. $9.42 million), as 2003 included a one-time recognition of $8.56 million in deferred revenue upon the termination of a collaboration with Micromet. Conversely, research and development contract revenue increased 112% to $3.46 million, driven by new collaborations with Genentech and Wyeth.
- Operating Expenses: Total costs and expenses decreased slightly to $20.58 million from $20.96 million. Research and development expenses fell 9% to $11.57 million due to the cessation of the ES Cell International collaboration and reduced spending on nervous system disorders, partially offset by increased spending on cancer programs. General and administrative expenses rose 16% to $7.56 million due to increased legal fees, professional services, and Sarbanes-Oxley compliance costs.
- Other Income: Other income increased significantly to $1.59 million (from an expense of $1.45 million in 2003) due to a net gain of $1.30 million from the settlement of a note receivable and equity investment in Micromet.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Co-Development Option: On January 28, 2005, Curis exercised a co-development option with Genentech for its lead product candidate (topical therapy for basal cell carcinoma). Curis will now share equally in U.S. development costs and future U.S. net profits/losses. Management estimates incurring approximately $20 million in development expenses through Phase II trials, with Phase II completion expected in mid-2007.
- Liquidity: As of December 31, 2004, the company held $49.5 million in cash and marketable securities. Management believes these resources are sufficient to fund operations into mid-2007, including the new co-development costs. Additional financing will likely be required thereafter.
- Revenue Recognition: The company expects to implement SFAS No. 123(R) in the third quarter of 2005, which will require expensing the fair value of stock-based compensation, potentially materially impacting future results.
Risks and Contingencies
- Dependence on Collaborators: Substantially all revenue is derived from collaborations (Genentech, Wyeth, Ortho Biotech). The company has no sales or marketing infrastructure.
- Regulatory Risk: All product candidates are in preclinical or early clinical stages. Success depends on FDA approval, which is uncertain and costly.
- Intellectual Property: The company relies on patents and trade secrets; infringement litigation or failure to secure patents could be material.
- Financing Needs: The company has an accumulated deficit of $663 million and will require substantial additional funding to continue operations beyond mid-2007.
Investor Verification Checklist
- Co-Development Costs: Verify the $20 million estimated cost for the Genentech basal cell carcinoma program and the timeline for Phase II completion (mid-2007).
- Cash Runway: Confirm the sufficiency of the $49.5 million cash balance to fund operations through mid-2007 given the new cost-sharing arrangement.
- Revenue Concentration: Note that 88% of 2004 revenue came from two partners: Wyeth (51%) and Genentech (37%).
- Stock-Based Compensation Impact: Assess the potential impact of the upcoming adoption of SFAS No. 123(R) on future net loss figures.
- Convertible Debt: Review the terms of the $5.71 million in convertible notes, including the recent conversion of the Elan note into common stock in January 2005.